Pretax income is the income that a company earns before paying income taxes. Madrigal Pharmaceuticals's pretax income for the
three
months ended in Mar. 2024 was $-147.54 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-444.28 Mil.
Madrigal Pharmaceuticals's pretax margin was %.
Madrigal Pharmaceuticals Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Madrigal Pharmaceuticals's Pre-Tax Income
For the Biotechnology subindustry, Madrigal Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's Pre-Tax Income falls into.
Madrigal Pharmaceuticals Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Madrigal Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-444.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals (NAS:MDGL) Pre-Tax Income Explanation
Madrigal Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Business Description
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MDGL has been successfully added to your 